Abstract: The present invention is to provide a fluorine-containing polymer having excellent light transmission in the vacuum ultraviolet region of not more than 193 nm, a monomer favorably used for preparing the fluorine-containing polymer, a process for preparing the fluorine-containing polymer, and uses of the fluorine-containing polymer. The fluorine-containing polymer has at least a repeated unit structure represented by the following formula (1) and has an absorption coefficient of not more than 3.0 &mgr;m−1 at 157 nm of ultraviolet rays.

Abstract: 1.

Abstract: There is provided a variable displacement type piston machine capable of reducing noise and vibration through reduction of pulsation of discharge fluid by reducing the variation of the rate of operating fluid that is flowing from a high pressure port to a low pressure port and a drain. On a slide surface (1a) of a valve plate (1) is provided an intermittent drain passage (5) in a manner that it directly communicates with neither a high pressure port (3a) nor an oil guide groove (4). When the high pressure port (3a) and a cylinder port (54a) are communicated with each other via the oil guide groove (4) and a back flow from the high pressure port (3a) to the cylinder port (54a) is generated, the intermittent drain passage (5) communicates with neither the high pressure port (3a) nor the cylinder port (54a). When a cylinder block (55) further rotates from the above state, the intermittent drain passage (5) communicates with the high pressure port (3a) via the cylinder port (54a).

Abstract: Novel agent for the propylaxis and treatment of heart failure, which comprises as an active ingredient a 2-oxo-imidazolidine compound of the formula: ##STR1## wherein R.sup.1 and R.sup.2 are the same or different and are each a lower alkyl group, R.sup.3 is a phenyl-substituted lower alkyl group, and R.sup.4 is a hydrogen atom or a lower alkyl group, or a pharmaceutically acceptable salt thereof.

Abstract: This invention relates to imidazolidinone compounds of the formula ##STR1## wherein Q is methylene group or a single bond:R is a heterocyclic group selected from the group consisting of pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl and 1,3-thiazolyl which may be unsubstituted or with a substituent selected from the group consisting of lower alkyl, lower alkoxy and halogen atom, wherein R is bonded to Q or, when Q is a single bond, to the imidazolidinone ring, through the carbon atom of R;the ring A is an unsubstituted phenyl or a substituted phenyl having 1 or 2 substituent(s) selected from the group consisting of lower alkyl, lower alkoxy, halogen, lower alkylthio, trihalogeno-lower alkyl and nitro;Y is vinylene group or ethynylene;m is a integer from 1 to 6 andn is 0, 1 or 2,or a pharmacetically acceptable salt thereof.These compounds aer useful as cerebral activators, anti-depressants and nootropic drugs.

Abstract: A quinazolinone derivative of the formula: ##STR1## wherein R is lower alkyl, lower alkoxy or halogen. Said quinazolinone derivative (I) or a pharmaceutically acceptable acid addition salt thereof is useful as central muscle relaxants.

Abstract: Novel 2-oxo-imidazolidine derivative of the formula: ##STR1## wherein R.sup.1 is lower alkyl or phenyl-lower alkyl, R.sup.2 is lower alkyl, R.sup.3 is alkyl of one to 12 carbon atoms or phenyl-lower alkyl and R.sup.4 is hydrogen or lower alkyl, and a pharmaceutically acceptable salts thereof are disclsoed. Said compounds (I) and salts thereof are useful as hypotensive agents.

Abstract: N-(2-amino-5-nitrobenzoyl)-o-toluidine is condensed with fluoroacetic acid or a functional derivative thereof. N-(2-fluoroacetamido-5-nitrobenzoyl)-o-toluidine obtained by said condensation reaction is dehydrated to produce 2-fluoromethyl-3-(o-tolyl)-6-nitro-4(3H)-quniazolinone, which is then subjected to reduction reaction. 2-fluoromethyl-3-(o-tolyl)-6-amino-4(3H)-quinazolinone thus obtained and a pharmaceutically acceptable acid addition salt thereof are useful as central muscle relaxants, minor tranquilizers, anti-convulsants, analgesics and/or anti-inflammatory agents.